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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
















print (not peer 
reviewed) 
• Using national health 
register-data, this 
observational cohort 
study found that 
infection with lineage 
B.1.1.7 was associated 
with an increased risk 
of hospitalisation 
compared with other 
lineages 
• This may have serious 
public health impact in 
countries with spread 
of B.1.1.7 and can 
support hospital 
preparedness and 
modelling of projected 





















• Here the novel SARS-
CoV-2 variant, VOC 
202012/01 (lineage 
B.1.1.7) is estimated 
to have a 43-90% 





modelling shows that 
VOC 202012/01 will 
lead to large 
resurgences of 
COVID-19 cases 
• In England, without 
stringent control 
measures, including 
limited closure of 
educational 





deaths in 2021 will 
exceed those in 2020 
with a similar 
transmission increase 
(59-74%) in Denmark, 
Switzerland and the 




















• Until effective vaccines are 
widely deployed, a COVID-19 
early warning system is vital in 




• It is observed here that 












activity anticipate increases in 
confirmed cases and deaths by 
2 to 3 weeks 
• Confirmed cases and deaths 
also decrease 2 to 4 weeks after 
NPI implementation, measured 
by anonymised, phone-derived 
human mobility data 
• Authors proposed that 
combining disparate health and 
behavioural data may help 
identify disease activity changes 

















• VOC B.1.1.7 is resistant 
to neutralisation by most 
monoclonal antibodies to 
the N-terminal domain 
(NTD) of the spike and 
relatively resistant to a 
few monoclonal 
antibodies to the 
receptor-binding domain 
(RBD). It is not more 
resistant to convalescent 
plasma or vaccinee sera 
• VOC B.1.351 is resistant 
to neutralisation by most 
monoclonal antibodies to 
the NTD of the spike and 
to multiple individual 
monoclonal antibodies to 
the RBD – largely owing 
to an E484K mutation. It 
is also more resistant to 
convalescent plasma and 
vaccinee sera 
• B.1.351 and emergent 
variants with similar 
spike mutations offer 
new challenges for 
monoclonal antibody 
therapy and threaten 















of an adverse 
clinical course 







The Lancet | 
Article 
• Azithromycin is an 
antibiotic with potential 
antiviral and anti-
inflammatory properties 
and has been used to 
treat COVID-19 but 
evidence from 
community trials is 
lacking 
• The effectiveness of 
azithromycin to treat 
suspected COVID-19 
among people in the 
community who had an 
increased risk of 
complications was 
assessed in this UK-




• Findings do not justify 
the routine use of 
azithromycin for reducing 
time to recovery or risk of 
hospitalisation for people 
with suspected COVID-
19 in the community 



























• First open-label, 
multicentre, randomised 
controlled, phase 3 trial 
of tocilizumab entirely in 
a lower-middle-income 
country 
• Trial conducted in 12 
public and private 
hospitals across India in 
180 adults >=18y 
admitted to hospital with 
moderate to severe 
COVID-19 with positive 
SARS-CoV-2 PCR test 
result 
• Findings do not support 
routine tocilizumab in 
patients admitted to 
hospital with moderate to 
severe COVID-19  
• Post-hoc evidence 
suggests tocilizumab 
may still be effective in 
tocilizumab 
patients with severe 
COVID-19 
















• 60-day, randomised, 
double-blind, placebo-
controlled, multinational 
phase 3 trial at 45 
hospitals of safety and 
efficacy of sarilumab, an 
IL-6 receptor inhibitor, in 
severe (requiring 
supplemental oxygen by 
nasal cannula or face 
mask) or critical 
(requiring greater 
supplemental oxygen, 
mechanical ventilation, or 
extracorporeal support) 
COVID-19  
• Sarilumab was not 
efficacious in patients 
admitted to hospital with 
severe COVID-19 
• Authors suggest 
adequately powered 
trials of targeted 
immunomodulatory 
therapies assessing 
survival as a primary 




















• Report on a series of 12 
patients with large local 
reactions to the mRNA-
1273 vaccines, median 
onset on day 8 (range 4 to 
11) after first dose 
• Not all patients had a 
recurrence of large local 
reactions after second 
dose 
• Authors encourage 
additional reporting and 
communication regarding 
the epidemiologic 
characteristics, causes and 






reactions which may 
reassure patient concerns, 
encourage completion of 
vaccination and minimise 
unnecessary antibiotic use 


















Health | Article 
• A survey of 311 clinicians 
from 213 hospitals 
worldwide finds that 
COVID-19 pandemic has 
had major impacts on 
childhood cancer care 
worldwide 
• 78% of hospitals 
surveyed between June 
and August 2020 reported 
that 43% made fewer new 
cancer diagnoses than 
expected, 34% noted a 
rise in number of patients 
abandoning treatment, 
and 7% closed their 
paediatric cancer units at 
some stage 
• Findings are more 





02.03.2021 Global trends 





CGD | Notes 
• Review and overlay of 
some of the features of 
the COVID crisis on 
earlier observed trends 
and dynamics 
• Exploration of some of the 
changes and trends in 
development agency 
strategic direction  
• 3 fundamental challenges 
that bilateral development 
agencies will need to 
address, and which will 
define their development 
cooperation and 
international partnerships  
Global 
trends 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
08.03.2021 Financing for Global Health Security and pandemic 
preparedness: taking stock and what’s next  
CGD | Blog 
06.03.2021 Single-dose Oxford-AstraZeneca COVID-19 
vaccine followed by a 12-week booster 
The Lancet | Comment 
06.03.2021 Medical oxygen crisis: a belated COVID-19 
response 
The Lancet | World Report 
05.03.2021 A ‘me’ first approach to vaccination won’t defeat 
Covid 
The Guardian | Opinion (Dr 
Tedros Adhanom 
Ghebreyesus) 
05.03.2021 RECOVERY trial closes recruitment to colchicine 
treatment for patients hospitalised with COVID-19 
RECOVERY | News 
05.03.2021 Challenges in the rollout of COVID019 vaccines 
worldwide 
The Lancet Respiratory 
Medicine | News 
05.03.2021 Desperation in the time of COVID-19 The Lancet Respiratory 
Medicine | Spotlight 
05.03.2021 From female warriors in the rainforest to infectious 
disease specialists: COVID-19 in the Amazon 
The Lancet Respiratory 
Medicine | Spotlight 
05.03.2021 Sex-disaggregated data in COVID-19 vaccine 
trials 
The Lancet | 
Correspondence 
05.03.2021 The USA’s response to the 2014 Ebola outbreak 
could have informed its COVID-19 response 
The Lancet | 
Correspondence 
05.03.2021 Long-haul COVID: heed the lessons from other 
infection-triggered illnesses 
The Lancet | 
Correspondence 
05.03.2021 COVID research updates: T cells might provide 
rescue from rampant COVID variants 
Nature | News 
04.03.2021 IL-6 blockade for COVID-19: a global scientific call 
to arms 
The Lancet Respiratory 
Medicine | Comment 
04.03.2021 Global health security requires endemic disease 
eradication 
The Lancet | Comment 
04.03.2021 US health agency will invest $1 billion to 
investigate ‘long COVID’ 
Nature | News 
03.03.2021 The social and emotional side of vaccine hesitancy SSHAP | Podcast 
03.03.2021 Choices in a Crisis – Individual preferences among 
SARS-CoV-2 vaccines 
NEJM | Perspective 
02.03.2021 An urgent call to collect data related to COVDI-19 
and Indigenous populations globally 
BMJ Global Health | 
Commentary 
02.03.2021 Communicating COVID-19 vaccines: lessons from 
the dengue vaccine controversy in the Philippines 
BMJ Global Health | 
Commentary 
01.03.2021 Africa’s contribution to the science of the COVID-
19/SARS-CoV-2 pandemic 
BMJ Global Health | 
Commentary 
01.03.2021 African authorship on African papers during the 
COVID-19 pandemic 
BMJ Global Health | 
Commentary 
01.03.2021 J&J’s single-dose COVID vaccine raises hopes for 
faster rollout 
Nature | News 
   
 
Dashboards & Trackers  












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 
















LSTM Stop TB 
Partnership 
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  Social 
Development 
Direct C19 blog 
series 



















Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 





Africa taking charge 
of its future: 
prioritizing gender 
equality in the path to 
recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for 
vaccination 




and Africa: where do 









Diseases in the 
COVID era 





for health workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
WHO & CGD 
Health systems 
1h 30 Joe Kutzin 
is the tole of PFM in 
the “new normal”? 
Governance & 
Financing 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 










online brief with Dr 
David Nabarro 
















training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
  
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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